E-selectin Gene Expression Is Induced Synergistically with the Coexistence of Activated Classic Protein Kinase C and Signals Elicited by Interleukin-1beta but Not Tumor Necrosis Factor-alpha *

Masahiro TamaruDagger and Shosaku NarumiDagger §

From the Dagger  Pharmaceutical Frontier Research Laboratories, Japan Tobacco, Inc., Central Pharmaceutical Research Institute, Yokohama, Kanagawa 236-0004, Japan and the § Department of Molecular Preventive Medicine, School of Medicine, University of Tokyo, Tokyo 113-0033, Japan

    ABSTRACT
Top
Abstract
Introduction
References

We have examined the effect of protein kinase C (PKC) on the expression of the E-selectin and intercellular adhesion molecule-1 (ICAM-1) mRNAs in human umbilical vein endothelial cells. The lower classic PKC activity on pretreatment with phorbol ester (phorbol 12-myristate 13-acetate (PMA)) for 24 h markedly decreased IL-1beta -induced E-selectin mRNA expression in the presence of fetal calf serum and basic fibroblast growth factor, although the induction of ICAM-1 mRNA expression was only influenced a little by the PKC down-regulation. On the other hand, tumor necrosis factor-alpha (TNFalpha )-induced gene expression of these adhesion molecules was unaffected by such PKC modulation. The intracellular signals generated by interleukin (IL)-1beta and TNFalpha themselves are not mediated through classic PKC activation, because the response to neither stimulant was inhibited by the PKC down-regulation in the absence of fetal calf serum and basic fibroblast growth factor. Simultaneous treatment with IL-1beta and PMA synergistically induced E-selectin gene expression but not when TNFalpha was substituted for IL-1beta . ICAM-1 mRNA expression was only additively induced on the cotreatment. The synergistic effect on E-selectin mRNA induction was independent of de novo protein synthesis and mediated by elevated transcriptional activity. Promoter analysis of E-selectin indicated that the NF-ELAM1/activating transcription factor element is critical for the synergistic effect of the cotreatment with IL-1beta and PMA.

    INTRODUCTION
Top
Abstract
Introduction
References

Adhesion molecules such as E-selectin, intercellular adhesion molecule-1 (ICAM-1),1 and vascular adhesion molecule-1 (VCAM-1) contribute to the recruitment of leukocytes not only during the inflammatory or immune response, but also during the injury following ischemia-reperfusion (1-5) and the development of atherosclerosis (6, 7). Indeed, there has been an explosion of interest in these topics, which has been fueled by remarkable advances in new therapies directed at several adhesion molecules (reviewed in Ref. 8). Most of these molecules are inducible and regulated through gene expression. Regulation of adhesion molecule expression has been largely studied in vitro using human umbilical vein endothelial cells (HUVEC), in which two monokines, IL-1 and TNFalpha , can induce these adhesion molecules in the same manner through NF-kappa B activation (9-11). However, a study involving dermal microvascular endothelial cells has shown that ICAM-1 is induced by either IL-1 or TNFalpha , whereas VCAM-1 is induced only by TNFalpha (12), suggesting that the signals generated by IL-1 and TNFalpha for adhesion molecule induction are different in part.

We have examined whether or not there is such tissue-specific regulatory control of the gene expression of adhesion molecules in vivo, since the expression of chemokine mRNAs following systemic treatment with proinflammatory cytokines was induced in a tissue-specific manner in mice (13, 14). Recently, we found that E-selectin mRNA expression following systemic treatment with IL-1beta was induced in the heart in a tissue-specific manner and that IL-1beta was a much stronger inducer of E-selectin mRNA than TNFalpha , while ICAM-1 and VCAM-1 were induced similarly by either IL-1beta or TNFalpha (15). We assumed the presence of heart-specific microenvironments as one reason. There are many stimuli that affect cells in various tissues, including localized cytokines, growth factors, and specific extracellular matrices. Although the intracellular signals elicited by them remain to be elucidated, some of them would induce the activation of protein kinase C (PKC) (16-21). Since E-selectin mRNA expression is also induced by treatments that activate PKC (22), we have examined the cooperative effect of PKC activation on IL-1beta - or TNFalpha -induced gene expression of E-selectin.

Our results indicate that although the intracellular signals generated by IL-1beta and TNFalpha themselves are not mediated through classic PKC activation, the coexistence of activated classic PKC and signals elicited by IL-1beta , but not TNFalpha , synergistically induces the expression of E-selectin mRNA via increased transcription. Furthermore, promoter analysis of the E-selectin gene suggests that NF-ELAM1/activating transcription factor (ATF) element is indispensable for the synergistic transcription of E-selectin induced by the combined treatment with IL-1beta and PMA.

    EXPERIMENTAL PROCEDURES

Reagents-- Dulbecco's phosphate-buffered saline, medium 199, and phorbol-12-myristate-13-acetate (PMA) were purchased from Life Technologies, Inc. Fetal calf serum (FCS) was purchased from Equitech-Bio (Ingram, TX). The penicillin/streptomycin solution, agarose, diethyl pyrocarbonate (DEP), dextran sulfate, and MOPS were from Sigma. Nick translation kits and proteinase K were purchased from Boehringer Mannheim Yamanouchi (Tokyo, Japan). Formamide and 50× Denhardt's solution were obtained from Wako Pure Chemical Industries Inc. (Osaka, Japan). RNase-free DNase was obtained from Promega (Madison, WI). Restriction endonucleases and T4 polynucleotide kinase were products of Takara Shuzo Co. (Otsu, Japan). NEN Life Science Products was the source of [alpha -32P]dCTP, [gamma -32P]ATP, and [alpha -32P]UTP. Recombinant human TNFalpha (9 × 107 units/mg) and recombinant human IL-1beta (2.8 × 108 units/mg) were from Genzyme Corp. (Cambridge, MA). Human recombinant basic fibroblast growth factor (bFGF) was obtained from Progen Biotechnik GmbH (Heidelberg, Germany). Collagen type 4 (Cellmatrix type 4) was from Nitta Gelatin Inc. (Osaka, Japan). Polyclonal antibodies against ATF-2, ATF-3, c-Jun, cAMP-responsive element-binding protein (CREB), NF-kappa B p50, p52, p65, Rel-B, and c-Rel were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). All other chemicals were obtained from Nacalai Tesque Inc. (Kyoto, Japan).

Cell Culture-- HUVEC were isolated from human umbilical cords using a perfusate obtained with trypsin (Life Technologies). HUVEC were serially passaged (in a 1:5 split ratio) and maintained in medium 199 containing 10% FCS, antibiotics (50 units/ml penicillin and 50 mg/ml streptomycin) and 10 ng/ml human recombinant bFGF. HUVEC were usually precultured in medium 199 supplemented with 0.5% FCS and antibiotics for 24 h before experiments. Tissue culture dishes were precoated with collagen type 4. HUVEC at the sixth to eighth passage were used for experiments.

Preparation of Plasmid DNA and Oligonucleotide Probes-- The plasmids encoding the genes for human ICAM-1 and E-selectin were purchased from British Biotechnology Ltd. (Oxford, United Kingdom). For Northern hybridization, plasmid DNA (1 mg) was radiolabeled by nick translation with [32P]dCTP to a specific activity of approximately 108 cpm/mg and was used at 7 × 106 cpm/blot. Double-stranded oligonucleotides containing the NF-ELAM1/ATF cis-element (-166 to -129) (5'-GAGACAGAGTTTCTGACATCATTGTAATTTTAAGCATC-3'), the oligonucleotides that introduced the mutations in the NF-ELAM1/ATF cis-element (5'-GAGACAGAGTTTCgtcgAgCcTTGTAATTTTAAGCATC-3'), the distal two kappa B consensus sequences (-128 to -101) (5'-GTGGATATTCCCGGGAAAGTTTTTGGAT-3'), or the proximal kappa B site (-100 to -75) (5'-GCCATTGGGGATTTCCTCTTTACTGG-3') in the E-selectin promoter region were synthesized. The oligonucleotides (10 pmol) were radiolabeled with T4 polynucleotide kinase and [gamma -32P] ATP to a specific activity of over 106 cpm/pmol.

Preparation of RNA and Northern Hybridization-- Total RNA was isolated from confluent HUVEC using guanidine isothiocyanate cesium chloride according to the previously published method (23). Equal amounts of RNA (20 µg) were denatured and subjected to electrophoresis in a 1% agarose-formaldehyde gel as described previously (24, 25). The RNA was then blotted by capillary transfer onto nylon membranes (Boehringer Mannheim Yamanouchi). The blots were prehybridized for 6 h at 42 °C in 50% formamide, 1% SDS, 5× SSC, 1× Denhardt's solution (0.02% Ficoll, 0.02% bovine serum albumin, and 0.02% polyvinylpyrrolidone), 0.25 mg/ml denatured herring testes DNA and 50 mM sodium phosphate buffer, pH 6.5. Hybridization was carried out at 42 °C for 12-18 h with 7 × 106 cpm of the denatured probe. The filters were washed for 30 min at room temperature in 0.1% SDS, 2× SSC and then for 15-30 min at 55 °C in the same solution. The blots were then exposed to XAR-5 x-ray film (Eastman Kodak Co.) with DuPont Cronex Lightening Plus intensifying screens at -70 °C. In some experiments, the blots were reutilized by stripping and rehybridization with different probes. Expression of beta -actin was used as an internal control and was applied in all experiments. In addition, the RNA load per lane was assessed by ethidium bromide staining of the original agarose gel after capillary transfer. In some experiments, the autoradiograms were quantified by videodensitometry, and the levels of mRNA were normalized relative to those of beta -actin.

Nuclear Run-on Transcription Assay-- HUVEC were treated as indicated in the text, and nuclei were isolated as described previously (26). Transcription that started in intact cells was allowed to reach completion in the presence of [alpha -32P]UTP, and then the RNA was isolated and hybridized to slot-blotted plasmids containing specific cDNA inserts (5 µg of DNA/slot) essentially as described elsewhere (27, 28). The blots were autoradiographed for 24-72 h at -70 °C as described above. The autoradiograms were quantified by videodensitometry, and the levels of transcripts were normalized relative to those of beta -actin.

Promoter-Luciferase Construction-- The wild-type fragment (-800 to +50) of the human E-selectin promoter was generated by polymerase chain reaction using two gene-specific primers and HUVEC genomic DNA as the template. The two primers carried base pair substitutions that introduced a BglII site at the 5'-end of the fragment (BglII (-800) primer, 5'-GCGAAGATCTGAGATGGCGTTTCTCCATGT-3') and a HindIII site at the 3'-end (HindIII primer, 5'-AGAGAAGCTTTGTCTCAGGTCAGTATAGGA-3'). The resulting fragment was cloned into the BglII and HindIII sites of the luciferase expression vector, PicaGene Basic Vector (Toyo Ink, Tokyo, Japan). The 5'-flanking restriction sites, SspI, AccI, NsiI, and SmaI, were used to generate -554, -382, -232, and -116 chimeras, respectively. Deletion mutants with end points at -166 and -129 were generated using the HindIII primer, and the BglII (-166) primer (5'-GCGAAGATCTGAGACAGAGTTTCTGACATCATTG-3') and BglII (-129) primer (5'-GCGAAGATCTCGTGGATATTCCCGGGAAAGT-3'), respectively. A mutant that introduced the mutations in the NF-ELAM1/ATF cis-element, mNF-ELAM1/ATF, was generated using the HindIII primer and the BglII (-166m) primer (5'-GCGAAGATCTGAGACAGAGTTTCgtcgAgCcTTG-3'). The resulting fragments were also cloned into the PicaGene Basic Vector. The 4× NF-ELAM1/ATF construct was made as follows. The double-stranded oligonucleotide carrying a XhoI site at the 5'-end and a BglII site at the 3'-end (5'-TCGAGTTTCTGACATCATTTTCTGACATCATTTTCTGACATCATTTTCTGACATCATA-3') was inserted into the XhoI/BglII sites of the PicaGene Promoter Vector (Toyo Ink), which only contains the SV40 virus minimal promoter.

DNA Transfection and Luciferase Assay-- HUVEC were plated onto six-well collagen-coated culture dishes (2 × 105 cells/well) 24 h prior to transfection. Transfection was performed with Lipofectin (Life Technologies) according to the manufacturer's recommendations. Briefly, reporter DNA (20 µg) was mixed with 2 µl of Lipofectin and up to 200 µl of serum-free medium (Opti-MEM; Life Technologies). After a 30-min incubation, further Opti-MEM (800 µl) was added, and the mixture was applied to cells that had been washed twice with Opti-MEM. Four hours later, the medium was changed to medium 199 containing 10% FCS and 10 ng/ml bFGF. After a 24-h culture, the medium was changed to medium 199 containing only 0.5% FCS, followed by culture for a further 24 h. After the indicated treatment for 6 h, the cells were harvested. The cells were lysed in 150 µl of lysis buffer (Toyo Ink), and 20 µl of the resultant extract was used for the luciferase assay (Toyo Ink). The luciferase activities were normalized relative to total protein concentrations of the cell extracts.

Preparation of Nuclear Extracts-- Nuclear extracts were prepared by a modification of the procedure of Dignam et al. (29). Cells were washed three times with phosphate-buffered saline, scraped off, and then harvested by centrifugation. The cells were resuspended and then incubated on ice for 15 min in hypotonic buffer A (10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM dithiothreitol, and 0.5 mM phenylmethylsulfonyl fluoride) and then vortexed for 10 s with 0.6% Nonidet P-40. Nuclei were separated from the cytosol by centrifugation at 12,000 × g for 60 s and then resuspended in buffer C (20 mM HEPES, pH 7.9, 25% glycerol, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, and 0.5 mM phenylmethylsulfonyl fluoride) and shaken for 30 min at 4 °C. Nuclear extracts were obtained by centrifugation at 12,000 × g. Protein concentrations were measured by means of the Bradford assay (Bio-Rad).

Electrophoretic Mobility Shift Assay (EMSA)-- For the binding reaction, nuclear extracts (10 µg of protein) were incubated in a total reaction mixture of 25 µl comprising 20 mM HEPES, pH 7.9, 80 mM NaCl, 0.1 mM EDTA, 1 mM dithiothreitol, 8% glycerol, and 2.5 µg of poly(dI-dC) (Amershan Pharmacia Biotech, Uppsala, Sweden). The radiolabeled oligonucleotide (105 cpm) was added to the mixture after preincubation for 15 min at 4 °C, and then the total reaction mixture was incubated for 20 min at room temperature. For antibody "supershift" analysis, 2 µg each of the indicated antibodies was added, followed preincubation for 1 h at 4 °C. Samples were loaded on 6% polyacrylamide gels in low ionic strength buffer (25 mM Tris, 22.5 mM borate, and 0.25 mM EDTA) and run at 15 V/cm with cooling. The gels were then dried and analyzed by autoradiography.

UV Cross-linking-- UV cross-linking was performed as described previously (30). Briefly, 80 mg of nuclear extract was incubated in a 100-µl total reaction mixture comprising 4 mM HEPES, pH 7.9, 5 mM Tris-HCl, pH 7.6, 1 mM EDTA, 0.2 mM dithiothreitol, 5% glycerol, 80 mM NaCl, and 20 µg of poly(dI-dC). The radiolabeled bromodeoxyuridine-substituted oligonucleotide (8 × 105 cpm) was then added to the reaction mixture. The preincubation and incubation times were as described above. The reaction mixture was then subjected to electrophoresis in a 6% polyacrylamide gel. After separation, the gel was placed in contact with the filter surface of a 302-nm UV transilluminator and irradiated for 10 min. The optimal exposure conditions for cross-linking were determined experimentally. The gel was then autoradiographed for 30 min. The region corresponding to the specific protein-DNA complex was located by inspection and excised. To each slice, 500 µl of a mixture comprising 125 mM Tris-HCl, pH 6.8, 4% SDS, 20% glycerol, and 10% 2-mercaptoethanol was added, followed by equilibration for 40 min. The gel slices were then loaded onto 1.5-mm-thick 10% polyacrylamide gels. The gels were stained with Coomassie Brilliant Blue, destained, dried under vacuum, and then subjected to autoradiography.

    RESULTS

Induction of E-selectin mRNA Expression Is Synergized by the Combined Treatment with IL-1beta /PMA, but Not with TNFalpha /PMA, through Elevated Transcriptional Activity-- Initially, we wished to determine if classic PKC activation was involved in the intracellular signaling pathway through which IL-1beta or TNFalpha induces E-selectin mRNA in HUVEC, since the PKC dependence of IL-1beta or TNFalpha -induced E-selectin mRNA expression has not been well defined (31). One reason for the discrepancy is that available PKC inhibitors such as H7 are not strictly specific for that kinase (32), and another reason is whether or not the culture medium during the period of HUVEC stimulation includes FCS and bFGF, which can activate classic PKC. Therefore, we examined the effect of PKC down-regulation, due to pretreatment with PMA, on the gene expression of E-selectin and ICAM-1 induced by IL-1beta or TNFalpha in the presence or absence of FCS and bFGF. HUVEC were precultured for 24 h with PMA (1 µg/ml) in medium 199 containing 10% FCS and 10 ng/ml of bFGF or containing only 0.5% FCS. Then the HUVEC were washed three times with phosphate-buffered saline and stimulated with IL-1beta (400 pg/ml) or TNFalpha (500 pg/ml) for 3 h. Total RNA was isolated and analyzed by Northern hybridization as to the specific mRNA content using radiolabeled probes for the E-selectin, ICAM-1, and beta -actin genes (Fig. 1). In the presence of FCS/bFGF, IL-1beta -induced E-selectin mRNA expression was strongly decreased after a 24-h pretreatment with PMA, whereas ICAM-1 mRNA induction was decreased only a little by such PKC down-regulation. Interestingly, TNFalpha -induced gene expression of E-selectin and ICAM-1 was unaffected by the classic PKC down-regulation. In contrast, in the absence of FCS/bFGF, pretreatment with PMA did not affect the inducibility of these genes upon treatment with either IL-1beta or TNFalpha . These data demonstrate that PKC-mediated pathways are not involved in the intracellular signaling pathways through which IL-1beta or TNFalpha induces gene expression of E-selectin and ICAM-1 and that classic PKC activation by FCS/bFGF and IL-1beta (but not TNFalpha ) cooperatively affects the selective induction of E-selectin mRNA expression in HUVEC.


View larger version (43K):
[in this window]
[in a new window]
 
Fig. 1.   Different effects of PKC down-regulation on E-selectin gene expression induced by IL-1beta or TNFalpha treatment in the presence or absence of FCS and bFGF. A, HUVEC were pretreated with PMA (1 µg/ml) for 24 h in the presence or absence of FCS and bFGF and then washed and stimulated with IL-1beta (400 pg/ml) or TNFalpha (500 pg/ml) for 3 h. At the end of the treatment, the cells were collected and subjected to Northern hybridization. B, the resulting autoradiographs were quantified by videodensitometry. The data are presented as the ratios of the optical density values to those of beta -actin.

To determine whether or not activated PKC synergizes with IL-1beta , but not with TNFalpha , to induce E-selectin mRNA expression, HUVEC were treated with IL-1beta or TNFalpha , either alone or in combination with PMA (100 ng/ml), in medium 199 containing only 0.5% FCS, without bFGF. Following autoradiography, the expression levels of E-selectin and ICAM-1 mRNA were normalized relative to that of beta -actin (Fig. 2). Treatment with IL-1beta , TNFalpha , or PMA stimulated equivalent gene expression of E-selectin and ICAM-1. The combined treatment with IL-1beta and PMA synergistically induced E-selectin mRNA expression, although the cotreatment had only an additive effect on the induction of ICAM-1 mRNA. In contrast, when TNFalpha was substituted for IL-1beta , the cotreatment with PMA had no synergistic effect on the gene expression of E-selectin or ICAM-1. These data demonstrate that classic PKC activation and the IL-1beta -induced intracellular signaling pathway, which differs from the TNFalpha -induced one, are necessary for full induction of E-selectin mRNA.


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 2.   Simultaneous treatment with IL-1beta and PMA synergistically induces E-selectin gene expression. Northern hybridization was performed with RNA from cells untreated or treated for 3 h with IL-1beta (400 pg/ml) or TNFalpha (500 pg/ml) either alone or in combination with PMA (100 ng/ml). The resulting autoradiographs were quantified by videodensitometry as described in the legend to Fig. 1B.

To confirm the markedly different effects of IL-1beta and TNFalpha on E-selectin mRNA expression in the presence of PMA, dose-response profiles for IL-1beta and TNFalpha were examined. HUVEC were treated with increasing doses of IL-1beta , ranging from 16 to 400 pg/ml, or TNFalpha , from 20 to 500 pg/ml, in the presence or absence of PMA (100 ng/ml) (Fig. 3). The dose curve for IL-1beta -mediated induction of E-selectin mRNA revealed that in the presence of PMA, E-selectin was cooperatively induced by IL-1beta in a dose-dependent manner. In contrast, E-selectin mRNA expression was only slightly increased by treatment with increasing doses of TNFalpha in the presence or absence of PMA.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 3.   IL-1beta cooperatively increases E-selectin mRNA expression in a dose-dependent manner in the presence of PMA. HUVEC were treated with increasing amounts of IL-1beta (0, 16, 80, and 400 pg/ml) or TNFalpha (0, 20, 100, and 500 pg/ml) with or without PMA (100 ng/ml) for 3 h. At the end of the treatment, the cells were collected and subjected to Northern hybridization. The resulting autoradiographs were quantified as described in the legend to Fig. 1B.

The synergistic effect of combined treatment with IL-1beta and PMA on E-selectin mRNA induction is independent of de novo protein synthesis, because it was potentiated and not inhibited by the presence of cycloheximide at the concentration (10 µg/ml) sufficient to inhibit protein synthesis by 95% (33) (data not shown).

To determine if the effects of IL-1beta , TNFalpha , and PMA on the gene expression of adhesion molecules are mediated by increased transcriptional activity of the genes, nuclear run-on studies were performed. HUVEC cultures were treated with IL-1beta and TNFalpha , either alone or in combination with PMA for 2 h; nuclei were isolated; and the transcription that had started in intact cells was allowed to reach completion in the presence of [32P]UTP. The radiolabeled RNA transcripts were subsequently hybridized to slot-blotted plasmid DNA fragments encoding E-selectin, ICAM-1, or beta -actin (Fig. 4). While either IL-1beta , TNFalpha , or PMA weakly stimulated transcription of the E-selectin gene, the combination of IL-1beta and PMA synergistically increased E-selectin transcription. In contrast, cotreatment with TNFalpha and PMA did not have a marked cooperative effect. On the other hand, ICAM-1 transcription was induced by IL-1beta , TNFalpha , or PMA, and treatment with either IL-1beta or TNFalpha combined with PMA had only an additive effect on the transcription of the gene. These results are largely consistent with the levels of specific mature mRNA found in total cellular RNA, indicating that the coexistence of classic PKC activation and the intracellular signals generated by IL-1beta , but not by TNFalpha , synergize E-selectin mRNA induction principally via the activation of specific transcription.


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 4.   Synergistic induction of E-selectin transcription by IL-1beta and PMA. A, HUVEC were untreated or treated for 2 h with IL-1beta (400 pg/ml) or TNFalpha (500 pg/ml), either alone or in combination with PMA (100 ng/ml). Following the isolation of nuclei, transcription was allowed to proceed in the presence of radiolabeled UTP, and then the generated RNA was detected by hybridization to slot-blotted plasmids containing specific cDNA inserts for E-selectin, ICAM-1, and beta -actin. B, the transcript levels for E-selectin and ICAM-1 were quantified by videodensitometry and normalized relative to those for beta -actin. The value for each gene in untreated cells was taken as 1.

The NF-ELAM1/ATF Site in the 5' Promoter Region of the E-selectin Gene Is Required for the Synergistic Expression Induced by Cotreatment with IL-1beta and PMA-- To identify the cis-regulatory sequences required for the synergistic effect of IL-1beta and PMA on induction of E-selectin mRNA expression, HUVEC were transiently transfected with a series of 5'-flanking deletion mutants inserted into a firefly luciferase expression vector. Twenty-four hours after transfection, FCS in the medium was reduced to 0.5%, and the HUVEC were cultured further for 24 h. Then the cells were treated for 6 h with IL-1beta or TNFalpha , either alone or in combination with PMA (100 ng/ml), and harvested for the luciferase assay. A transient transfection study on HUVEC with a deletion mutant with 800 bp upstream of the transcription start site demonstrated that simultaneous treatment with IL-1beta and PMA induced the luciferase activity synergistically, while cotreatment with TNFalpha and PMA caused only additive induction (Fig. 5B), as found in nuclear run-on studies (Fig. 4). This result demonstrates that the promoter region from -800 to +50 bp of the E-selectin gene is sufficient for the synergistic effect of IL-1beta and PMA. As shown in Fig. 5C, all of the deletion mutants from 800 to 166 bp upstream of the transcription start site induced luciferase activity to equivalent levels in response to cotreatment with IL-1beta and PMA. However, the deletion mutant with 116 bp of the upstream sequence was not able to induce the luciferase gene synergistically in response to the cotreatment, indicating that a critical promoter region involved in the synergistic E-selectin gene expression on cotreatment with IL-1beta and PMA lies within the -166 to -116 bp region. As shown in Fig. 5A, this region between -166 and -116 bp of the E-selectin promoter gene contains one NF-ELAM1/ATF site (34, 35) and one NF-kappa B site, which was recently identified (11, 36, 37). To further delineate the precise element(s) within the -166 to -116 bp region required for the synergism between IL-1beta and PMA, we constructed a deletion mutant with 129 bp of the upstream sequence in which the NF-ELAM1/ATF site was deleted and examined its luciferase inducibility (Fig. 6A). The 166-bp of the upstream sequence was able to induce the synergistic expression of the luciferase gene in response to simultaneous treatment with IL-1beta and PMA, whereas only additive induction was seen when TNFalpha was substituted for IL-1beta . However, a reporter construct with 129 bp of the upstream sequence did not exhibit synergistic induction of the luciferase gene at all. To further confirm that the synergistic effect of IL-1beta and PMA is mediated through the NF-ELAM1/ATF site, we created a reporter construct with 166 bp of the upstream sequence into whose NF-ELAM1/ATF site a mutation was introduced. It has been reported that the dATP residues at -151 and -146 bp are important for the binding of ATF proteins to the NF-ELAM1/ATF site of the E-selectin promoter (34). So we introduced the same mutations at the NF-ELAM1/ATF site (mNF-ELAM1/ATF) and assayed the luciferase activity (Fig. 6B). As expected, the reporter construct with mNF-ELAM1/ATF did not cause synergistic induction of the luciferase gene in response to combined treatment with IL-1beta and PMA. These results clearly demonstrate that the NF-ELAM1/ATF site is indispensable for the synergistic transcription of E-selectin induced by simultaneous treatment with IL-1beta and PMA. Next, to clarify that only the NF-ELAM1/ATF site is necessary and sufficient for the synergism between IL-1beta and PMA, we made a reporter construct driven by a 4 times repeated NF-ELAM1/ATF site (4× NF-ELAM1/ATF) and assayed the luciferase activity (Fig. 6C). Although the activity was induced a little by each treatment, synergistic induction in response to combined treatment with IL-1beta and PMA was never observed. This indicates that the NF-ELAM1/ATF site is necessary but not sufficient for the synergistic transcription of E-selectin induced by simultaneous treatment with IL-1beta and PMA.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 5.   Identification of the promoter elements critical for the synergistic induction by IL-1beta and PMA. A, schematic representation of the E-selectin promoter. The previously described 5'-flanking elements containing binding sites for NF-ELAM1 and NF-kappa B are shown. The positions of the 5' end point used in the deletion analysis are indicated with arrows. B, HUVEC were transfected transiently with the wild type (-800) reporter construct. After a 24-h incubation with 0.5% FCS, HUVEC were left untreated or treated with IL-1beta (400 pg/ml) or TNFalpha (500 pg/ml), either alone or in combination with PMA (100 ng/ml) for 6 h. HUVEC extracts were prepared and assayed for luciferase activity. The value obtained from untreated cells was taken as 1. C, luciferase activity was assayed in HUVEC transiently transfected with each reporter construct and untreated or treated with IL-1beta /PMA for 6 h. The value obtained from the untreated cells transfected with the -800 construct was taken as 1. The results in B and C are presented as the means ± S.E. of the means for triplicate samples, and at least three independent experiments were performed with similar results.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 6.   The NF-ELAM1/ATF site is required for the synergistic transcription of E-selectin induced by cotreatment with IL-1beta and PMA. A, HUVEC transfected with -166, -129, or -116 deleted construct as described in the legend to Fig. 5A were untreated or treated with IL-1beta (400 pg/ml) or TNFalpha (500 pg/ml), either alone or in combination with PMA (100 ng/ml) for 6 h. The value obtained with the -166 construct in untreated cells was taken as 1. B, the -166 deleted construct with (mNF-ELAM1/ATF) or without the point mutations at the NF-ELAM1/ATF site was transfected into HUVEC and analyzed as described for A. The value obtained with the wild type -166 construct in untreated cells was taken as 1. C, the construct containing 4× NF-ELAM1/ATF sites was transfected and analyzed as described in A. The value obtained from untreated cells was taken as 1. The results shown in A, B, and C are representative of three identical experiments performed. The results are the means ± S.E.

Synergistic Transcription Induced by Combined Treatment with IL-1beta and PMA Does Not Occur through the Changed DNA Binding Activity of NF-ELAM1 and NF-kappa B-- The NF-ELAM1/ATF site is recognized by members of the ATF family of transcription factors, including ATFa, ATF2, and ATF3 (35). It has been reported that homo- or heterodimers consisting of not only these members of the ATF family but also c-Jun and CREB bind to the ATF site of the E-selectin promoter (35, 38). Furthermore, Kaszubska et al. have demonstrated that each of the three ATF members has a different effect on E-selectin promoter activity (35). Therefore, we examined if the nuclear proteins that bind to the NF-ELAM1/ATF site of the E-selectin promoter differed quantitatively or qualitatively, depending on the stimulant, such as IL-1beta , TNFalpha , and PMA, either alone or in combination. Nuclear extracts were prepared from HUVEC treated for 2 h with IL-1beta or TNFalpha , either alone or in combination with PMA (100 ng/ml), and then the EMSA was performed using a oligonucleotide probe including the NF-ELAM1/ATF site at -166 to -129 bp of the E-selectin promoter (Fig. 7, A and B). As reported previously (38), three distinct complexes (C1-C3) were detected constitutively. Although the presence of PMA decreased the amount of the C1 complex, there was neither quantitative nor qualitative difference in the binding of NF-ELAM1 to the specific DNA sequence between the combined treatments with IL-1beta /PMA and TNFalpha /PMA. Because the reporter construct with mNF-ELAM1/ATF sequence did not cause synergistic induction of the luciferase gene in response to the cotreatment with IL-1beta and PMA (Fig. 6B), we next examined the effect of mNF-ELAM1/ATF sequence on the EMSA using the nuclear extracts from HUVEC treated with IL-1beta /PMA and TNFalpha /PMA (Fig. 7C). Only the faint binding activity to the mNF-ELAM1/ATF oligonucleotides was seen using both nuclear proteins, and the binding activities of both nuclear proteins to the NF-ELAM1/ATF site was slightly inhibited by the mNF-ELAM1/ATF sequence to the same extent, while they were completely inhibited by the NF-ELAM1/ATF oligonucleotides. These results demonstrate that the binding of NF-ELAM1 to the corresponding cis-element is indispensable for the synergistic transcriptional activity of E-selectin induced by the cotreatment with IL-1beta /PMA and that the binding affinities of both the NF-ELAM1 activated by the treatment with IL-1beta /PMA and TNFalpha /PMA were the same.


View larger version (40K):
[in this window]
[in a new window]
 


View larger version (43K):
[in this window]
[in a new window]
 
Fig. 7.   DNA binding activity and protein composition of NF-ELAM1 are not different between both treatments with IL-1beta /PMA and TNFalpha /PMA. HUVEC were either left untreated or treated with IL-1beta (400 pg/ml) or TNFalpha (500 pg/ml) either alone or in combination with PMA (100 ng/ml) for 2 h, and then nuclear extracts were prepared. A, electrophoretic mobility shift assay with a radiolabeled oligonucleotide containing the NF-ELAM1/ATF site. B, quantification of the complexes (C1-C3) by videodensitometry using the resulting autoradiographs. C, binding affinity to the wild type and mutated NF-ELAM1/ATF site on the EMSA using the nuclear extracts treated with IL-1beta or TNFalpha in combination with PMA. w and m, wild type and mutated NF-ELAM1/ATF site, respectively. D, supershift analysis with polyclonal antibodies against ATF2, ATF3, c-Jun, and CREB, using nuclear extracts of HUVEC treated with IL-1beta /PMA for 2 h. E, protein compositions of C2 and C3 complexes from nuclear extracts in HUVEC treated with IL-1beta /PMA and TNFalpha /PMA. C2 and C3 complexes obtained from EMSA (A) were analyzed using the UV cross-linking method described under "Experimental Procedures." Molecular mass markers are indicated at the left in kilodaltons. The arrows show location of the proteins involved.

To identify the protein complexes binding to the NF-ELAM1/ATF site in the nuclear extracts of HUVEC treated with IL-1beta and TNFalpha in combination with PMA, we performed supershift analysis with polyclonal antibodies against ATF2, ATF3, c-Jun, and CREB. In HUVEC treated with IL-1beta /PMA, the antibodies against ATF2 and ATF3 caused shifts in the mobilities of the C2 and C3 complex in part, respectively, and anti-c-Jun antibody caused shifts in both the C2 and C3 complexes, while the anti-CREB antibody caused no shift (Fig. 7D). With the nuclear extracts of HUVEC stimulated with TNFalpha /PMA, the antibodies had the same effects on the mobilities of the C2 and C3 complexes as mentioned above (data not shown), suggesting that the composition of the proteins binding to the NF-ELAM1/ATF site was not different between HUVEC treated with IL-1beta and TNFalpha in combination with PMA. Furthermore, UV cross-linking experiments on the C2 and C3 complexes from HUVEC treated with IL-1beta /PMA and TNFalpha /PMA showed that the C2 and C3 complexes contained four proteins and two proteins, respectively, whose protein compositions on both treatments appeared to be identical on the basis of SDS-PAGE mobility (Fig. 7E).

Direct protein-protein associations are important mechanisms by which transcription factors synergistically cooperate. Since ATF family members and c-Jun have been shown to physically interact with NF-kappa B, a quantitative or qualitative difference in NF-kappa B may be responsible for the NF-ELAM1/ATF-dependent synergistic transcription of the E-selectin gene induced by IL-1beta /PMA but not by TNFalpha /PMA treatment. EMSA involving an oligonucleotide probe containing two distal kappa B sites (-128 to -101 bp) or the other proximal one (-100 to -75 bp) of the E-selectin promoter sequence showed that while two complexes (Ckappa 1 and Ckappa 2) were induced on treatment with IL-1beta , TNFalpha , or PMA in the same manner, combined treatment with IL-1beta /PMA or TNFalpha /PMA did not cause synergistically quantitative or qualitative change in NF-kappa B activation (Fig. 8, A and B). Supershift analyses involving the antibodies against p50, p52, p65, Rel-B, and c-Rel with nuclear extracts of HUVEC stimulated with IL-1beta /PMA (Fig. 8C) and TNFalpha /PMA (data not shown) at the proximal kappa B site revealed that Ckappa 1 was a p50/p65 heterodimer and Ckappa 2 was a p50 homodimer. In addition, UV cross-linking experiments on the Ckappa 1 and Ckappa 2 complexes showed that there was no difference between nuclear extracts from HUVEC treated with IL-1beta /PMA and TNFalpha /PMA (data not shown).


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 8.   Analysis of DNA binding activity to the kappa B sites in the E-selectin promoter. Nuclear extracts were prepared as described in Fig. 7, and the electrophoretic mobility shift assay was performed with a radiolabeled oligonucleotide containing distal kappa B sites (-128 to -101 bp) (A) or the other proximal one (-100 to -75 bp) (B) of the E-selectin promoter. C, supershift analysis of the proximal kappa B site with polyclonal antibodies against p50, p52, p65, Rel-B, and c-Rel, using nuclear extracts of HUVEC treated with IL-1beta /PMA.


    DISCUSSION

While phorbol ester PMA principally activates classic protein kinase C (31, 39, 40) and is capable of inducing the expression of E-selectin as well as other adhesion molecules (22, 31), whether or not IL-1beta and TNFalpha induce the expression through PKC activation has not been well defined (31). In this study, we have clarified that the IL-1beta - or TNFalpha -provoked intracellular signaling pathway that induces gene expression of E-selectin and ICAM-1 is not through classic PKC activation (Fig. 1). To further confirm this, we also assayed PKC activation, which was assessed as PKC translocation in HUVEC following treatment with IL-1beta , TNFalpha , or PMA. Although PMA caused a rapid decrease in PKC activity in the cytoplasmic fraction and a proportional increase in the membrane fraction, such PKC activation was not detected upon treatment with IL-1beta or TNFalpha (data not shown).

However, our results demonstrated that PKC activation, which occurred in the presence of FCS and bFGF as well as PMA, induced E-selectin gene expression synergistically with IL-1beta but not with TNFalpha , while such a synergistic effect was not observed on the expression of ICAM-1 (Figs. 1-3). Since HUVEC are usually cultured in a medium containing FCS and FGF, the synergistic effect of activated PKC and signals elicited by IL-1beta is one reason why the PKC dependence of E-selectin mRNA expression induced by proinflammatory cytokines has been misunderstood. Although it has been reported that IL-1 and TNFalpha induce NF-kappa B activation, which is indispensable for the expression of adhesion molecules (reviewed in Ref. 41) through ceramide formation (42), some studies have suggested that signals generated by both proinflammatory cytokines differ, at least in part (12, 43). Swerlick et al. have shown that ICAM-1 was induced on cultured dermal microvessel endothelium by either IL-1 or TNFalpha , whereas VCAM-1 was induced only by TNFalpha (12). Treatment of HUVEC with the combination of IFNgamma and TNFalpha induced the surface expression of ICAM-1 and E-selectin, whereas the combination of IL-1beta and IFNgamma had a minimal effect (43). Furthermore, our recent study demonstrated that IL-1beta is a much stronger inducer of E-selectin mRNA than TNFalpha in the heart, although both proinflammatory cytokines induce ICAM-1 and VCAM-1 mRNAs to similar extents (15). From these observations, there appear to be both common (NF-kappa B activation) and specific pathways of endothelial adhesion molecule expression induced by IL-1beta and TNFalpha , although what kinds of signals generated by both cytokines result in stimulus-specific induction of adhesion molecules has never been clarified. Since the promoter regions of endothelial adhesion molecule genes contain kappa B elements in common and specific regulatory elements such as the NF-ELAM1/ATF site in E-selectin, the Sp1 and interferon regulatory factor binding sites in VCAM-1 and the CCAAT enhancer-binding protein element and gamma -activated sequences in ICAM-1 (reviewed in Ref. 41), the different effects of IL-1beta and TNFalpha on the full expression of adhesion molecules may result from the different modulation of nuclear factors that can bind to these specific regulatory elements.

Indeed, our results (Fig. 6) demonstrated that the NF-ELAM1/ATF site of the E-selectin promoter is required for the synergistic expression induced by the cotreatment with IL-1beta and PMA and that the individual transcriptional activities of NF-kappa B and NF-ELAM1 are not involved in the synergistic effect of treatment with IL-1beta /PMA.

Various publications on E-selectin reporter constructs containing multiple point mutations or deletions that abrogate NF-ELAM1 binding differ in the effects described (11, 34-38). The results range from unchanged to reduced basal reporter activity or to severely decreased induction by IL-1beta or TNFalpha . Variations in transfection protocols as well as reporter genes, leading to differences in the detection limits of the respective reporter assays, and whether or not the NF-ELAM1/ATF site was upstream of the wild-type E-selectin promoter or of a minimal heterologous promoter (SV40) might explain the divergent results and interpretations. Although the effects of the two proinflammatory stimulants were never compared in these publications, a survey comparing the effects of IL-1beta and TNFalpha under similar experimental conditions, mentioned in the publications, led us to the suggestion that the NF-ELAM1/ATF site is much more necessary for full transcription of the E-selectin gene when IL-1beta is used as the stimulant than when TNFalpha is used.

Since it has been reported that cAMP inhibits TNF-induced E-selectin promoter activity through alteration of the composition of nuclear factors that bind to the NF-ELAM1/ATF element (38), we have considered that the synergistic effect of combined treatment with IL-1beta and PMA might occur through the same mechanism. However, EMSAs together with supershift experiments and UV cross-linking studies involving HUVEC nuclear extracts showed no differences in the binding activity and the protein composition of NF-ELAM1 between combined treatment with IL-1beta /PMA and TNFalpha /PMA (Fig. 7, A-C), demonstrating that the synergistic effect of IL-1beta and PMA on the induction of E-selectin mRNA expression is not dependent on the binding activity or protein composition of NF-ELAM1. Since direct physical interaction between the proteins (ATFa, ATF2, ATF3, and c-Jun) bound to the NF-ELAM1/ATF element and NF-kappa B subunits (p50 and p65) has been demonstrated and reported to be the mechanism underlying the cooperativity yielding maximal levels of E-selectin gene transcription (34, 35), the binding activity and protein composition of NF-kappa B activated by combined treatment with IL-1beta and PMA have been examined in comparison with NF-kappa B induced by cotreatment with TNFalpha /PMA (Fig. 8). The results showed no differences in the binding activity or protein composition of NF-kappa B activated by both combined treatments and the direct transcriptional activity mentioned above. Therefore, increased transactivation of NF-ELAM1 and/or NF-kappa B in conjunction with each other, which cannot be detected on EMSA, is most likely the mechanism through which E-selectin expression is induced synergistically upon combined treatment with IL-1beta and PMA but not with TNFalpha /PMA.

Recently, it was reported that ATF2 is phosphorylated as well as c-Jun by proinflammatory cytokines or ultraviolet radiation through the c-Jun NH2-terminal protein kinase cascade and that the transcriptional activity of the phosphorylated ATF2 increases without changes in its DNA binding activity (44). In the same report, it was suggested that ATFa is also a substrate of c-Jun NH2-terminal protein kinase. Although IL-1beta and TNFalpha , as well as phorbol ester, were all reported to be potent activators of c-Jun NH2-terminal protein kinase in several cells (45-48), the effects of the two proinflammatory cytokines alone or in combination with PMA have not been compared. Another subgroup of mitogen-activated protein (MAP) kinases, the p38 family, also strongly phosphorylate ATF2 but phosphorylate c-Jun very weakly (49-51). Interestingly, at least two members of the p38 family (p38 and p38-2) have been shown to be activated more strongly by IL-1beta than TNFalpha or PMA in COS cells (50), corresponding to the finding in this study that IL-1beta is a more potent stimulant in combination with PMA for E-selectin transcription than TNFalpha in vascular endothelial cells. This is also consistent with our finding in a recent in vivo study that IL-1beta is a much stronger inducer of E-selectin in the heart (15). Furthermore, p38 MAP kinases such as p38, p38-2, and p38beta have been shown to be expressed at very high levels in the heart in a tissue-specific manner (49, 50), in accord with our observation of E-selectin induction in vivo (15). Therefore, it is suggested that p38 MAP kinases play key roles in tissue- and stimulus-specific expression of E-selectin through phosphorylation and increased transactivational ability of ATF2 and/or its family. However, since other groups have reported that p38 MAP kinases are activated to similar extents by IL-1beta and TNFalpha in HeLa cells (49, 51) or that both p38 and c-Jun NH2-terminal protein kinase are activated with different time courses by the two proinflammatory cytokines (52), it is necessary to study, using vascular endothelial cells, the effects of IL-1beta and TNFalpha in combination with PMA not only on the activation of MAP kinases (p38 and c-Jun NH2-terminal protein kinase) but also on the phosphorylation and transactivational abilities of ATF2 and its family as well as c-Jun.

    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Dept. of Molecular Preventive Medicine, School of Medicine, University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-0033, Japan. Tel.: 81-3-3812-2111 (ext. 3433); Fax: 81-3-5800-6853; E-mail: snarumi{at}tka.att.ne.jp.

The abbreviations used are: ICAM-1, intercellular adhesion molecule-1; VCAM, vascular adhesion molecule-1; HUVEC, human umbilical vein endothelial cell(s); IL, interleukin; TNF, tumor necrosis factor; PKC, protein kinase C; ATF, activating transcription factor; PMA, phorbol 12-myristate 13-acetate; FCS, fetal calf serum; bFGF, basic fibroblast growth factor; CREB, cAMP-responsive element-binding protein; EMSA, electrophoretic mobility shift assay; bp, base pair(s); MOPS, 3-(N-morpholino)propanesulfonic acid.
    REFERENCES
Top
Abstract
Introduction
References

  1. Repine, J., Cheronis, J., Rodell, T., Linas, S., and Patt, A. (1987) Am. Rev. Respir. Dis. 136, 483-485[Medline] [Order article via Infotrieve]
  2. Horgan, M. J., Wright, S. D., and Malik, A. B. (1990) Am. J. Physiol. 259, L315-L319[Abstract/Free Full Text]
  3. Simpson, P. J., Todd, R. F., Fantone, J. C., Michelson, J. K., Griffin, J. D., and Lucchesi, B. R. (1988) J. Clin. Invest. 81, 624-629[Medline] [Order article via Infotrieve]
  4. Dreyer, W. J., Michael, L. H., West, M. S., Smith, C. W., Rothline, R., Rossen, R. D., Anderson, D. C., and Entman, M. L. (1991) Circulation 84, 400-411[Abstract]
  5. Colletti, L., Remick, D., Burtch, G., Kunkel, S., Strieter, R., and Campbell, D. (1990) J. Clin. Invest. 85, 1936-1943[Medline] [Order article via Infotrieve]
  6. Cybulsky, M. I., and Gimbrone, M. A., Jr. (1991) Science 251, 788-791[Medline] [Order article via Infotrieve]
  7. Ross, R. (1993) Nature 362, 801-809[CrossRef][Medline] [Order article via Infotrieve]
  8. Carlos, T. M., and Harlan, J. M. (1994) Blood 84, 2068-2101[Abstract/Free Full Text]
  9. Voraberger, G., Schafer, R., and Stratowa, C. (1991) J. Immunol. 147, 2777-2786[Abstract/Free Full Text]
  10. Neish, A. S., Williams, A. J., Palmer, H. J., Whitley, M. Z., and Collins, T. (1992) J. Exp. Med. 176, 1583-1593[Abstract]
  11. Schindler, U., and Baichwal, V. R. (1994) Mol. Cell. Biol. 14, 5820-5831[Abstract]
  12. Swerlick, R. A., Lee, K. H., Li, L. J., Sepp, N. T., Caughman, S. W., and Lawley, T. J. (1992) J. Immunol. 149, 698-705[Abstract/Free Full Text]
  13. Narumi, S., Wyner, L. M., Stoler, M. H., Tannenbaum, C. S., and Hamilton, T. A. (1992) J. Leukocyte Biol. 52, 27-33[Abstract]
  14. Ohmori, Y., Wyner, L., Narumi, S., Armstrong, D., Stoler, M., and Hamilton, T. A. (1993) Am. J. Pathol. 142, 861-870[Abstract]
  15. Tamaru, M., Tomura, K., Sakamoto, S., Tezuka, K., Tamatani, T., and Narumi, S. (1998) Arterioscler. Thromb. Vasc. Biol. 18, 1292-1303[Abstract/Free Full Text]
  16. Farrar, W. L., Thomas, T. P., and Anderson, W. B. (1985) Nature 315, 235-237[Medline] [Order article via Infotrieve]
  17. Smith, R. J., Sam, L. M., Leach, K. L., and Justen, J. M. (1992) J. Leukocyte Biol. 52, 17-26[Abstract]
  18. Presta, M., Maier, J., and Ragnotti, G. (1989) J. Cell Biol. 109, 1877-1884[Abstract]
  19. Ha, K. S., and Exton, J. H. (1993) J. Biol. Chem. 268, 10534-10539[Abstract/Free Full Text]
  20. Gimond, C., and Aumailley, M. (1992) Exp. Cell Res. 203, 365-373[Medline] [Order article via Infotrieve]
  21. Green, J., Schotland, S., Stauber, D. J., Kieeman, C. R., and Clemens, T. L. (1995) Am. J. Physiol. 268, C1090-C1103[Abstract/Free Full Text]
  22. Ritchie, A. J., Johnson, D. R., Ewenstein, B. M., and Pober, J. S. (1991) J. Immunol. 146, 3056-3062[Abstract/Free Full Text]
  23. Chirgwin, J. M., Pryzbyla, R. J., MacDonald, R. J., and Rutter, W. J. (1979) Biochemistry 18, 5294-5299[Medline] [Order article via Infotrieve]
  24. Perbal, B. (1988) A Practical Guide to Molecular Cloning, John Wiley & Sons, Inc., New York
  25. Thomas, P. S. (1983) Methods Enzymol. 100, 255-266[Medline] [Order article via Infotrieve]
  26. Groudine, M., Peretz, M., and Weintraub, H. (1981) Mol. Cell. Biol. 1, 281-288[Medline] [Order article via Infotrieve]
  27. Greenberg, M. E., and Ziff, E. B. (1984) Nature 311, 433-438[Medline] [Order article via Infotrieve]
  28. Introna, M., Bast, R. C., Jr., Johnston, P. A., Adams, D. O., and Hamilton, T. A. (1987) J. Cell. Physiol. 131, 36-42[Medline] [Order article via Infotrieve]
  29. Dignam, J. D., Lebovitz, R. M., and Roeder, R. G. (1983) Nucleic Acids Res. 11, 1475-1489[Abstract]
  30. Narumi, S., Tebo, J. M., Finke, J. H., and Hamilton, T. A. (1992) J. Immunol. 149, 529-534[Abstract/Free Full Text]
  31. Montgomery, K. F., Osborn, L., Hession, C., Tizard, R., Goff, D., Vassallo, C., Tarr, P. I., Bomsztyk, K., Lobb, R., Harlan, J. M., and Pohlman, T. H. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 6523-6527[Abstract/Free Full Text]
  32. Hidaka, H., Inagaki, M., Kawamoto, S., and Sasaki, Y. (1984) Biochemistry 23, 5036-5041[Medline] [Order article via Infotrieve]
  33. Hamilton, T. A., Jansen, M. M., Somers, S. D., and Adams, D. O. (1986) J. Cell. Physiol. 128, 9-17[Medline] [Order article via Infotrieve]
  34. van Huijsduijnen, R. H., Whelan, J., Pescini, R., Becker-Andre, M., Schenk, A. M., and DeLamarter, J. F. (1992) J. Biol. Chem. 267, 22385-22391[Abstract/Free Full Text]
  35. Kaszubska, W., van Huijsduijnen, R. H., Ghersa, P., Deraemy-Schenk, A. M., Chen, B. P. C., Hai, T., DeLamarter, J. F., and Whelan, J. (1993) Mol. Cell. Biol. 13, 7180-7190[Abstract]
  36. Whitley, M. Z., Thanos, D., Read, M. A., Maniatis, T., and Collins, T. (1994) Mol. Cell. Biol. 14, 6464-6475[Abstract]
  37. Lewis, H., Kaszubska, W., DeLamarter, J. F., and Whelan, J. (1994) Mol. Cell. Biol. 14, 5701-5709[Abstract]
  38. De Luca, L. G., Johnson, D. R., Whitley, M. Z., Collins, T., and Pober, J. S. (1994) J. Biol. Chem. 269, 19193-19196[Abstract/Free Full Text]
  39. Nishizuka, Y. (1984) Nature 308, 693-698[Medline] [Order article via Infotrieve]
  40. Vyas, S., Biguet, N. F., and Mallet, J. (1990) EMBO J. 9, 3707-3712[Abstract]
  41. Collins, T., Read, M. A., Neish, A., Whitley, M. Z., Thanos, D., and Maniatis, T. (1995) FEBS Lett. 9, 899-909
  42. Kolesnick, R., and Golde, D, W. (1994) Cell 77, 325-328[Medline] [Order article via Infotrieve]
  43. Doukas, J., and Pober, J. S. (1990) J. Immunol. 145, 1727-1733[Abstract/Free Full Text]
  44. Gupta, S., Campbell, D., Derijard, B., and Davis, R. J. (1995) Science 267, 389-393[Medline] [Order article via Infotrieve]
  45. Derijard, B., Hibi, M., Wu, I. H., Barrett, T., Su, B., Deng, T., Karin, M., and Davis, R. J. (1994) Cell 76, 1025-1037[Medline] [Order article via Infotrieve]
  46. Sluss, H. K., Barrett, T., Derijard, B., and Davis, R. J. (1994) Mol. Cell. Biol. 14, 8376-8384[Abstract]
  47. Hibi, M., Lin, A., Smeal, T., Minden, A., and Karin, M. (1993) Genes Dev. 7, 2135-2148[Abstract]
  48. Kyriakis, J. M, Banerjee, P., Nikolakaki, E., Dai, T., Rubie, E. A., Ahmad, M. F., Avruch, J., and Woodgett, J. R. (1994) Nature 369, 156-160[CrossRef][Medline] [Order article via Infotrieve]
  49. Jiang, Y., Chen, C., Li, Z., Guo, W., Gegner, J. A., Lin, S., and Han, J. (1996) J. Biol. Chem. 271, 17920-17926[Abstract/Free Full Text]
  50. Stein, B., Yang, M. X., Young, D. B., Janknecht, R., Hunter, T., Murray, B. W., and Barbosa, M. S. (1997) J. Biol. Chem. 272, 19509-19517[Abstract/Free Full Text]
  51. Kumar, S., McDonnell, P. C., Gum, R. J., Hand, A. T., Lee, J. C., and Young, P. R. (1997) Biochem. Biophys. Res. Commun. 235, 533-538[CrossRef][Medline] [Order article via Infotrieve]
  52. Raingeaud, J., Gupta, S., Rogers, J., Dickens, M., Han, J., Ulevitch, R. J., and Davis, R. J. (1995) J. Biol. Chem. 270, 7420-7426[Abstract/Free Full Text]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.